The Addition of Arsenic Trioxide to Low Dose Ara-C in Older Patients with AML Does Not Improve Outcome

[1]  H. Dombret,et al.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Keith Wheatley,et al.  Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials , 2009, British journal of haematology.

[3]  R. Hills,et al.  Low dose Ara-C versus low Dose Ara-C and Tipifarnib: result of the UK NCRI AML16 "Pick a Winner" comparison [Abstract] , 2008 .

[4]  M. Mazumdar,et al.  Arsenic trioxide and low‐dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia , 2008, Cancer.

[5]  M. Sorror,et al.  Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. , 2007, Blood.

[6]  R. Hills,et al.  A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.

[7]  H. Kantarjian,et al.  The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. , 2007, British journal of haematology.

[8]  F. Wiklund,et al.  Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival , 2006, Leukemia.

[9]  S. Parmar,et al.  Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. , 2004, Leukemia research.

[10]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Patrick Royston,et al.  Novel designs for multi‐arm clinical trials with survival outcomes with an application in ovarian cancer , 2003, Statistics in medicine.

[12]  C. Earle,et al.  The outcomes and costs of acute myeloid leukemia among the elderly. , 2002, Archives of internal medicine.

[13]  E. Thiel,et al.  Dual effects of arsenic trioxide (As2O3) on non‐acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation , 2002, British journal of haematology.